These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

74 related items for PubMed ID: 7207127

  • 1. [Behavior of serum acid phosphatases following specific immunotherapy of metastasizing prostatic carcinoma].
    Rothauge CF, Kraushaar J, Gutschank J, Sedlacek HH.
    Med Welt; 1981 Jan 09; 32(2):50-3. PubMed ID: 7207127
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [Treatment of advanced metastasizing carcinoma of the prostate with estracyt (author's transl)].
    Rambausek M, Lutherer S, Terhorst B.
    Urologe A; 1981 Jul 09; 20(4):223-7. PubMed ID: 7196632
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Activity of phosphatase in the blood serum in prostatic carcinoma depending on the stage of the tumor].
    Wehnert J, Meissner D.
    Z Urol Nephrol; 1976 Apr 09; 69(4):243-50. PubMed ID: 952097
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Contribution on the clinical aspects of prostatic carcinoma].
    Sladczyk E.
    Z Arztl Fortbild (Jena); 1967 Jul 01; 61(13):657-60. PubMed ID: 5598256
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Serum prostatic acid phosphatase: an increase associated with a metastatic carcinoid tumor.
    Martini F, Pannacciulli I.
    J Natl Cancer Inst; 1991 Apr 03; 83(7):511. PubMed ID: 2005634
    [No Abstract] [Full Text] [Related]

  • 13. [Determination of acid phosphatase in prostatic carcinoma].
    Bauer HW, Walther V, Schmiedt F.
    Fortschr Med; 1980 Sep 11; 98(34):1301-5. PubMed ID: 7461538
    [Abstract] [Full Text] [Related]

  • 14. [Treatment of prostatic carcinoma from the endocrinologic viewpoint].
    Rothauge CF, Wildberger JE, Szasz G, Graef V.
    Urologe; 1969 Sep 11; 8(5):237-9. PubMed ID: 5359388
    [No Abstract] [Full Text] [Related]

  • 15. [Tissue polypeptide antigen as a marker for prostatic neoplasms. Preliminary study].
    Ruibal A, Durán P, Ibarz L, Fraile M, Roca I, de Torres Mateos JA.
    Arch Esp Urol; 1984 Sep 11; 37(5):399-403. PubMed ID: 6517625
    [No Abstract] [Full Text] [Related]

  • 16. [The determination of serum phosphatases].
    Dauchy F.
    Presse Med (1893); 1968 Mar 02; 76(11):523-4. PubMed ID: 5646258
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial.
    Burch PA, Croghan GA, Gastineau DA, Jones LA, Kaur JS, Kylstra JW, Richardson RL, Valone FH, Vuk-Pavlović S.
    Prostate; 2004 Aug 01; 60(3):197-204. PubMed ID: 15176049
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.